Open Accessp53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose
Author(s) -
Chompunoot Sinthupibulyakit,
Kristopher R. Grimes,
Frederick E. Domann,
Yong Xu,
Fang Fang,
Wanida Ittarat,
Daret K. St. Clair,
William St Clair
Publication year - 2009
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo_00000372
Subject(s) - a549 cell , cancer research , clonogenic assay , radiation therapy , radiosensitivity , lung cancer , apoptosis , glycolysis , cell cycle , cancer cell , oncogene , biology , cancer , radiosensitizer , chemistry , medicine , endocrinology , metabolism , biochemistry
Metabolic change in cancer cells by preferential production of energy through glycolysis is a well-documented characteristic of cancer. However, whether inhibition of glycolysis will enhance the efficacy of radiation therapy is a matter of debate. In this study which uses lung cancer as the model, we demonstrate that the improvement of radiotherapy by 2-deoxy-D-glucose (2DG) is p53-dependent. Based on clonogenic survival data, we show that p53-deficient lung cancer cells (H358) are more sensitive to 2DG treatment when compared to p53 wild-type lung cancer cells (A549). The effective doses of 2DG at 0.5-surviving fraction of A549 and H358 are 17.25 and 4.61 mM, respectively. Importantly, 2DG exhibits a significant radiosensitization effect in A549 cells but not in H358 cells. Treatment with 2DG increases radiation-induced p53 protein levels in A549 cells. siRNA inhibition of p53 in A549 cells reduces the radiosensitization effect of 2DG. Furthermore, ectopic expression of wild-type p53 in H358 cells significantly enhances the radiosensitization effect of 2DG as determined by colony formation assay. In nude mice injected with A549 cells, treatment of 2DG enhances the efficacy of radiation therapy. Together, these results suggest that inhibition of glycolysis may only be beneficial for radiation therapy of cancer expressing wild-type p53.